Package | hl7.terminology |
Type | CodeSystem |
Id | v3-nciThesaurus |
FHIR Version | R5 |
Source | http://terminology.hl7.org/https://build.fhir.org/ig/HL7/UTG/CodeSystem-v3-nciThesaurus.html |
URL | http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl |
Version | 3.0.0 |
Status | active |
Date | 2022-10-13T00:00:00-04:00 |
Name | NciThesaurus |
Title | NCI Thesaurus |
Realm | uv |
Authority | hl7 |
Description | NCI Thesaurus NCI Thesaurus is a biomedical thesaurus created specifically to meet the needs of the cancer research community, especially those engaged in translational research NCI Thesaurus is produced by the NCI Enterprise Vocabulary Services project. The NCI Thesaurus is provided under an open content license. |
Content | not-present |
CodeSystem | |
cmc-hierarchy-supplement | PQ-CMC-FDA NCIt Hierarchy Supplement |
ValueSet | |
PatientMilitaryStatus | Patient Military Status |
cdisc-yes-no-vs | CDISC Yes No Unknown Not Applicable Value Set |
ddf-study-title-type-vs | CDISC DDF Study Title Type Value Set |
m11-amendment-scope-enrollment-vs | Study Amendment Scope Enrollment Value Set |
m11-identifier-type-vs | M11 Identifier Type Value Set |
m11-phase-vs | M11 Phase Value Set |
m11-section-codes-vs | M11 Section Codes Value Set |
m11-study-amendment-reason-vs | Study Amendment Reaason Value Set |
m11-study-amendment-scope-vs | Study Amendment Scope Value Set |
nci-study-role-vs | NCI Study Role Value Set |
mcode-all-risk-assessment-value-vs | Acute Lymphoblastic Leukemia (ALL) Risk Assessment Value Set |
mcode-binet-stage-value-vs | Binet Stage Value Set |
mcode-cancer-stage-type-vs | Cancer Stage Type Value Set |
mcode-cancer-stage-value-vs | Cancer Stage Value Set |
mcode-cancer-staging-method-vs | Cancer Staging Method Value Set |
mcode-deauville-scale-vs | Deauville Scale Value Set |
mcode-figo-stage-value-vs | FIGO Stage Value Set |
mcode-international-retinoblastoma-stage-value-vs | International Retinoblastoma Stage Value |
mcode-lansky-play-performance-vs | Lansky Play Performance Status VS |
mcode-lymphoma-stage-value-vs | Lymphoma Stage Value Set |
mcode-lymphoma-staging-method-vs | Lymphoma Staging System Value Set |
mcode-myeloma-iss-stage-value-vs | International Staging System (ISS) for Myeloma Stage Value Set |
mcode-myeloma-riss-stage-value-vs | Revised International Staging System (ISS) for Multiple Myeloma Stage Value Set |
mcode-neuroblastoma-INRGSS-value-vs | International Neuroblastoma Risk Group Staging System (INRGSS) for Neuroblastoma Risk Assessment Value Set |
mcode-pretext-stage-value-vs | PRETEXT Stage Value |
mcode-rai-stage-value-vs | Rai Stage Value Set |
mcode-rai-staging-method-vs | Rai Staging System Value Set |
mcode-rhabdomyosarcoma-assessment-value-vs | Rhabdomyosarcoma Assessment Value Set |
mcode-rhabdomyosarcoma-clinical-group-value-vs | Rhabdomyosarcoma Clinical Group Value |
mcode-risk-assessment-type-vs | Risk Assessment Type Value Set |
mcode-risk-assessment-vs | Risk Assessment Value Set |
mcode-tnm-staging-method-vs | TNM Staging Method Value Set |
adverse-event-clinical-research-causality-relatedness | Adverse Event Clinical Research Causality Relatedness |
adverse-event-clinical-research-grades | Adverse Event Clinical Research Grades |
adverse-event-clinical-research-outcomes | Adverse Event Clinical Research Outcomes |
adverse-event-clinical-research-seriousness-criteria | Adverse Event Clinical Research Seriousness Criteria |
propertyColor | Color of the product |
propertyFlavor | Flavor of the product |
propertyShape | Shape of the product |
DiagnosticMarker | Diagnostic Marker |
HistologicalDiagnosis | HistologicalDiagnosis |
TumorGrade | Tumor Grade |
TumorProgression | Tumor Progression |
TumorStage | Tumor Stage |
phenotypic-abnormality | Phenotypic abnormality ValueSet |
codexrt-radiotherapy-adverse-event-termVS | Adverse Event Terms Value Set |
valueset-businessOperationQualifiers | Business Operation Qualifiers |
valueset-establishmentBusinessOperations | Establishment Business Operations |
valueset-gdufaFacilityBusinessOperationQualifiers | GDUFA Facility Business Operation Qualifiers |
valueset-gdufaFacilityBusinessOperations | GDUFA Facility Business Operations |
valueset-labelerBusinessOperations | Labeler Business Operations |
valueset-splColor | SPL Color |
valueset-splComboProductType | SPL Combo Product Type |
valueset-splDoseForm | SPL Dose Form |
valueset-splFlavor | SPL Flavor |
valueset-splMarketingCategories | SPL Marketing Categories |
valueset-splOperationType | SPL Operation Type |
valueset-splPackageTypes | SPL Package Types |
valueset-splRouteOfAdministration | SPL Route of Administration |
valueset-splShape | SPL Shape |
valueset-splSpecialMeasures | SPL Special Measures |
capsule-classification-category | Capsule Shell Classification Terminology |
cmc-product-name-types-vs | Product Name Types Terminology |
pqcmc-batch-utilization-terminology | Batch utilization Terminology |
pqcmc-chemical-structure-datafile-type-terminology | Chemical Structure Data File Type Terminology |
pqcmc-closure-type-terminology | Closure Type Terminology |
pqcmc-coating-purpose | Coating Purpose Terminology |
pqcmc-container-type-terminology | Container Type Terminology |
pqcmc-drug-product-component-function-category-terminology | Drug Product Component Function Category Terminology |
pqcmc-excipient-function-terminology | Excipient Function Terminology |
pqcmc-impurity-classification-terminology | Impurity Classification Terminology |
pqcmc-manufactured-dose-form-terminology | Manufactured Dose Form Terminology |
pqcmc-product-part-ingredient-physical-location | Ingredient Location Terminology |
pqcmc-product-part-type | Product Part Type Terminology |
pqcmc-quality-benchmark-terminology | Quality Benchmark Terminology |
pqcmc-release-mechanism | Release Mechanism Terminology |
pqcmc-release-profile | Release Profile Terminology |
pqcmc-representation-types | Representation Types |
pqcmc-source-type-terminology | Source Type Terminology |
pqcmc-specification-status-terminology | Specification Status Terminology |
pqcmc-specification-type-terminology | Specification Type Terminology |
pqcmc-strength-type-terminology | Strength Type Terminology |
pqcmc-substance-name-type | Substance Name Type |
pqcmc-test-category-terminology | Test Category Terminology |
pqcmc-test-method-origin-terminology | Test Method Origin Terminology |
pqcmc-test-usage-terminology | Test Usage Terminology |
spl-drug-route-of-administration-terminology | Drug Route Of Administration Terminology |
spl-pharmaceutical-dosage-form-terminology | Pharmaceutical Dosage Form Terminology |
substance-classification | Substance Classification |
molecular-biomarker-code-vs | Molecular Biomarker Codes |
nfdi4health-vs-mds-cd-datacollected-nci | NFDI4Health Data Collected [NCI] |
nfdi4health-vs-mds-cd-information-sources-nci-local | NFDI4Health Data Collected [NCI] |
nfdi4health-vs-mds-id-type-nci-local | NFDI4Health VS MDS ID Type [NCI, local] |
nfdi4health-vs-mds-identifier-type-related-artifact-nci-local | NFDI4Health VS MDS Identifier Type Related Artifact [NCI, local] |
nfdi4health-vs-mds-mortality-data-nci | NFDI4Health VS MDS Mortality Data [NCI] |
nfdi4health-vs-mds-ne-instrument-nci-local | NFDI4Health NE Instrument [NCI, Local] |
nfdi4health-vs-mds-ne-mode-nci-msh-local | NFDI4Health NE Mode [NCI, MeSH, Local] |
nfdi4health-vs-mds-organisational-roles-nci-local | NFDI4Health VS MDS Organisational Roles [NCI, local] |
nfdi4health-vs-mds-personal-roles-nci-local | NFDI4Health VS MDS Personal Roles [NCI, local] |
nfdi4health-vs-mds-population-coverage-nci | NFDI4Health VS MDS Population Coverage [NCI] |
nfdi4health-vs-mds-resource-type-general-nci-msh-local | NFDI4Health VS MDS Resource Type General [NCI, MSH, local] |
nfdi4health-vs-mds-resource-type-nci-local | NFDI4Health VS MDS Resource Type [NCI, Local] |
nfdi4health-vs-mds-study-allocation-nci | NFDI4Health VS MDS Study Allocation [NCI] |
nfdi4health-vs-mds-study-arm-group-type-nci | NFDI4Health VS MDS Study Arm Group Type [NCI] |
nfdi4health-vs-mds-study-assessments-sct-nci | NFDI4Health VS MDS Study Assessments [SCT, NCI] |
nfdi4health-vs-mds-study-biospecimen-retention-nci | NFDI4Health VS MDS Study Biospecimen Retention [NCI] |
nfdi4health-vs-mds-study-conditions-classification-nci-local | NFDI4Health VS MDS Study Conditions Classification [NCI, Local] |
nfdi4health-vs-mds-study-data-sharing-plan-ds-sct-nci | NFDI4Health VS MDS Study Data Sharing Plan Datashield [SCT, NCI] |
nfdi4health-vs-mds-study-data-sharing-plan-sup-inf-nci-local | NFDI4Health VS MDS Study Data Sharing Plan Supporting Information [NCI, local] |
nfdi4health-vs-mds-study-data-sources-general-nci-local | NFDI4Health VS MDS Study Data Sources General [NCI, local] |
nfdi4health-vs-mds-study-data-sources-imaging-nci | NFDI4Health VS MDS Study Data Sources Imaging [NCI] |
nfdi4health-vs-mds-study-data-sources-omics-nci | NFDI4Health VS MDS Study Data Sources Omics [NCI] |
nfdi4health-vs-mds-study-ds-biosamples-sct-nci | NFDI4Health VS MDS Study Data Sources Biosamples [SCT, NCI] |
nfdi4health-vs-mds-study-ethics-committee-approval-nci-local | NFDI4Health VS MDS Study Ethics Commitee Approval [NCI, local] |
nfdi4health-vs-mds-study-exposure-type-nci | NFDI4Health VS MDS Study Exposure Type [NCI] |
nfdi4health-vs-mds-study-group-characteristics-nci | NFDI4Health VS MDS Study Group Characteristics [NCI] |
nfdi4health-vs-mds-study-intervention-type-nci | NFDI4Health VS MDS Study Intervention Type [NCI] |
nfdi4health-vs-mds-study-masking-roles-nci-local | NFDI4Health VS MDS Study Masking Roles [NCI, local] |
nfdi4health-vs-mds-study-outcome-type-nci | NFDI4Health VS MDS Study Outcome Type [NCI] |
nfdi4health-vs-mds-study-overall-status-nci-local | NFDI4Health VS MDS Study Overall Status [NCI, Local] |
nfdi4health-vs-mds-study-phase-nci | NFDI4Health VS MDS Study Phase [NCI] |
nfdi4health-vs-mds-study-primary-design-nci | NFDI4Health VS MDS Study Primary Design [NCI] |
nfdi4health-vs-mds-study-primary-purpose-hl7-nci | NFDI4Health VS MDS Study Primary Purpose [HL7, NCI] |
nfdi4health-vs-mds-study-recruitment-register-nci-sct-local | NFDI4Health VS MDS Study Recruitment Register [NCI, SCT, Local] |
nfdi4health-vs-mds-study-sampling-method-nci-local | NFDI4Health VS MDS Study Sampling Method [NCI, local] |
nfdi4health-vs-mds-study-sampling-method-non-prob-nci-local | NFDI4Health VS MDS Study Sampling Method Non Probability [NCI, local] |
nfdi4health-vs-mds-study-sampling-prob-method-nci-local | NFDI4Health VS MDS Study Sampling Probability Method [NCI, Local] |
nfdi4health-vs-mds-study-time-perspectives-nci | NFDI4Health VS MDS Study Time Perspectives [NCI] |
nfdi4health-vs-mds-study-type-interventional-nci | NFDI4Health VS MDS Study Type Interventional [NCI] |
nfdi4health-vs-mds-study-type-non-interventional-nci-msh-local | NFDI4Health VS MDS Study Type Non Interventional [NCI, MSH, local] |
nfdi4health-vs-mds-yes-no-undecided-nci | NFDI4Health VS MDS Yes, No, Undecided [ NCI] |
adverse-event-clinical-research-causality-relatedness | Adverse Event Clinical Research Causality Relatedness |
adverse-event-clinical-research-grades | Adverse Event Clinical Research Grades |
adverse-event-clinical-research-outcomes | Adverse Event Clinical Research Outcomes |
adverse-event-clinical-research-seriousness-criteria | Adverse Event Clinical Research Seriousness Criteria |
deid-parameter-names | De-identification Parameter Names |
device-note-types | Device Note Type Codes |
2.16.840.1.113762.1.4.1021.30 | AdministrationUnitDoseForm |
2.16.840.1.113762.1.4.1021.46 | Device Magnetic resonance (MR) Safety |
2.16.840.1.113762.1.4.1021.47 | Device Latex Safety |
2.16.840.1.113762.1.4.1021.48 | Implantable Device Status |
2.16.840.1.113762.1.4.1032.292 | Non pharmacologic treatments for chronic pain NCI |
2.16.840.1.113762.1.4.1032.36 | Non pharmacologic treatments for chronic pain |
2.16.840.1.113762.1.4.1260.100 | MMR Proficient |
2.16.840.1.113762.1.4.1260.11 | Estrogen Receptor Test for Orserdu |
2.16.840.1.113762.1.4.1260.116 | Localized Bladder Cancer Staging |
2.16.840.1.113762.1.4.1260.119 | Localized Bladder Cancer T Stage |
2.16.840.1.113762.1.4.1260.128 | FGFR3 Gene |
2.16.840.1.113762.1.4.1260.13 | HER2 Negative |
2.16.840.1.113762.1.4.1260.131 | FGFR3 Gene Interpretation Positive NCI |
2.16.840.1.113762.1.4.1260.133 | FGFR3 Gene Interpretation Positive |
2.16.840.1.113762.1.4.1260.135 | FGFR3 Gene Interpretation Negative NCI |
2.16.840.1.113762.1.4.1260.137 | FGFR3 Gene Interpretation Negative |
2.16.840.1.113762.1.4.1260.138 | FGFR3 Molecular Variants |
2.16.840.1.113762.1.4.1260.190 | Localized NSCLC Stage Group NCIM |
2.16.840.1.113762.1.4.1260.192 | Localized NSCLC Stage Group |
2.16.840.1.113762.1.4.1260.198 | EGFR Gene |
2.16.840.1.113762.1.4.1260.203 | EGFR Generic Molecular Variant NCIM |
2.16.840.1.113762.1.4.1260.206 | EGFR Molecular Variants Osimertinib PM |
2.16.840.1.113762.1.4.1260.214 | Radiation Treatment Delivery NCIM |
2.16.840.1.113762.1.4.1260.216 | Radiation Treatment Delivery |
2.16.840.1.113762.1.4.1260.227 | MET Exon 14 skipping molecular variant |
2.16.840.1.113762.1.4.1260.235 | ROS1 Repotrectinib Molecular Variants |
2.16.840.1.113762.1.4.1260.237 | ROS1 Negative (geneinterpretation) NCI |
2.16.840.1.113762.1.4.1260.238 | ROS1 Negative (geneinterpretation) SNOMEDCT,NCI |
2.16.840.1.113762.1.4.1260.240 | ROS1 results (HGNC) |
2.16.840.1.113762.1.4.1260.246 | RET Negative (geneinterpretaion) NCI |
2.16.840.1.113762.1.4.1260.247 | RET Negative (geneinterpretaion) SNOMEDCT,NCI |
2.16.840.1.113762.1.4.1260.248 | RET Fusion Molecular Variants |
2.16.840.1.113762.1.4.1260.25 | ESR1 Gene Test |
2.16.840.1.113762.1.4.1260.26 | ESR1 Genetic Mutation |
2.16.840.1.113762.1.4.1260.260 | ALK Positive (geneinterpretation) NCI |
2.16.840.1.113762.1.4.1260.261 | ALK Positive (geneinterpretation) SNOMEDCT NCI |
2.16.840.1.113762.1.4.1260.263 | ALK Negative (geneinterpretation) NCI |
2.16.840.1.113762.1.4.1260.264 | ALK Negative (geneinterpretation) SNOMEDCT NCI |
2.16.840.1.113762.1.4.1260.277 | Extensive SCLC Stage Group NCIM |
2.16.840.1.113762.1.4.1260.278 | Extensive SCLC Stage Group |
2.16.840.1.113762.1.4.1260.28 | Her2 Negative |
2.16.840.1.113762.1.4.1260.30 | HER2 Positive |
2.16.840.1.113762.1.4.1260.305 | HER2 Negative (geneinterpretation/Labtestvalue) NCI |
2.16.840.1.113762.1.4.1260.307 | HER2 Negative (geneinterpretation/Labtestvalue) |
2.16.840.1.113762.1.4.1260.311 | Localized_Solid_Cancer_Stage Group NCIM |
2.16.840.1.113762.1.4.1260.313 | Localized_Solid_Cancer_Stage Group |
2.16.840.1.113762.1.4.1260.314 | Locally_Advanced_Solid_Cancer_Stage Group NCIM |
2.16.840.1.113762.1.4.1260.315 | Locally_Advanced_Solid_Cancer_Stage Group |
2.16.840.1.113762.1.4.1260.316 | Metastatic_Solid_Cancer_Stage Group NCIM |
2.16.840.1.113762.1.4.1260.317 | Metastatic_Solid_Cancer_Stage Group |
2.16.840.1.113762.1.4.1260.319 | Solid Cancer T Stage NCI |
2.16.840.1.113762.1.4.1260.32 | HER2 Positive |
2.16.840.1.113762.1.4.1260.320 | Solid Cancer T Stage codes |
2.16.840.1.113762.1.4.1260.325 | RET fusion Molecular Variants_Solid_Cancer |
2.16.840.1.113762.1.4.1260.344 | PTEN_gene |
2.16.840.1.113762.1.4.1260.346 | PIK3CA_gene |
2.16.840.1.113762.1.4.1260.348 | AKTI_gene |
2.16.840.1.113762.1.4.1260.350 | Progesterone_receptor_gene |
2.16.840.1.113762.1.4.1260.352 | Estrogen_receptor_gene |
2.16.840.1.113762.1.4.1260.359 | HER2_IHC_test_Gene |
2.16.840.1.113762.1.4.1260.372 | HER2 test_gene |
2.16.840.1.113762.1.4.1260.416 | KRAS_G12C_MV |
2.16.840.1.113762.1.4.1260.429 | Localized_Endometerial_Stage Group NCIM |
2.16.840.1.113762.1.4.1260.460 | Localized_Endometerial_Stage Group_SNOMED/NCIM |
2.16.840.1.113762.1.4.1260.465 | NTRK Repotrectinib Molecular Variants |
2.16.840.1.113762.1.4.1260.55 | MSI High |
2.16.840.1.113762.1.4.1260.57 | Early Stage IIB or lower |
2.16.840.1.113762.1.4.1260.60 | MMR Deficient |
2.16.840.1.113762.1.4.1260.61 | Stage IIB or lower and limited |
2.16.840.1.113762.1.4.1260.63 | Stage III or higher |
2.16.840.1.113762.1.4.1260.64 | Stage III or higher |
2.16.840.1.113762.1.4.1260.66 | Staging Unknown |
2.16.840.1.113762.1.4.1260.67 | Staging Unknown |
2.16.840.1.113762.1.4.1260.84 | RAS Gene Interpretation Negative NCM |
2.16.840.1.113762.1.4.1260.85 | RAS Gene Negative |
2.16.840.1.113762.1.4.1260.9 | ER Test for Orserdu |
2.16.840.1.113762.1.4.1260.91 | MSI High NCI |
2.16.840.1.113762.1.4.1260.94 | MSI Low NCI |
2.16.840.1.113762.1.4.1260.95 | MSI Low |
2.16.840.1.113762.1.4.1260.96 | MMR Deficient NCI |
2.16.840.1.113762.1.4.1260.99 | MMR Proficient NCI |
2.16.840.1.113762.1.4.1267.22 | Route of Administration of Therapeutic Agents |
2.16.840.1.113883.3.88.12.3221.8.11 | Medication Product Form |
2.16.840.1.113883.3.88.12.3221.8.7 | SPL Drug Route of Administration Terminology |
anforderung-liquidBiopsy | ValueSet - nNGM - Anforderung Liquid Biopsy |
anforderung-molekularpathologie | ValueSet - nNGM - Anforderung Molekularpathologie |
MaterialTyp | ValueSet - nNGM - MaterialTyp |
tki-resistenz | ValueSet - nNGM - TKI Resistenz |
No resources found
Note: links and images are rebased to the (stated) source
Generated Narrative: CodeSystem v3-nciThesaurus
This case-sensitive code system http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
defines codes, but no codes are represented here
{ "resourceType": "CodeSystem", "id": "v3-nciThesaurus", "text": { "status": "generated", "div": "<!-- snip (see above) -->" }, "url": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl", "identifier": [ { "system": "urn:ietf:rfc:3986", "value": "urn:oid:2.16.840.1.113883.3.26.1.1" } ], "version": "3.0.0", "name": "NciThesaurus", "title": "NCI Thesaurus", "status": "active", "experimental": false, "date": "2022-10-13T00:00:00-04:00", "publisher": "TBD - External Body", "contact": [ { "name": "National Cancer Institute" } ], "description": "NCI Thesaurus NCI Thesaurus is a biomedical thesaurus created specifically to meet the needs of the cancer research community, especially those engaged in translational research NCI Thesaurus is produced by the NCI Enterprise Vocabulary Services project. The NCI Thesaurus is provided under an open content license.", "caseSensitive": true, "content": "not-present" }